Danaher Corporation $DHR Holdings Raised by Mutual of America Capital Management LLC

Key Points

• Mutual of America Capital Management LLC increased its stake in Danaher Corporation by 4.9%, now owning 77,965 shares valued at approximately $15.4 million.
• Danaher reported earnings of $1.80 per share for the last quarter, exceeding expectations of $1.64, along with a revenue of $5.94 billion.
• The company announced a quarterly dividend of $0.32 per share, with an upcoming payment date of October 31st for stockholders on record as of September 26th.

Mutual of America Capital Management LLC grew its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 4.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 77,965 shares of the conglomerate's stock after purchasing an additional 3,647 shares during the period. Mutual of America Capital Management LLC's holdings in Danaher were worth $15,401,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of DHR. Nuveen LLC purchased a new stake in shares of Danaher during the first quarter valued at $833,941,000. Invesco Ltd. lifted its holdings in shares of Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. lifted its stake in Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock worth $295,550,000 after acquiring an additional 1,072,617 shares in the last quarter. Generation Investment Management LLP lifted its stake in Danaher by 33.2% in the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate's stock worth $651,515,000 after acquiring an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC lifted its stake in Danaher by 23.3% in the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate's stock worth $784,745,000 after acquiring an additional 722,636 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of DHR stock opened at $209.14 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $275.51. The stock's 50-day moving average is $201.60 and its two-hundred day moving average is $197.24. The firm has a market cap of $149.76 billion, a P/E ratio of 44.50, a PEG ratio of 2.98 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period in the prior year, the firm posted $1.72 EPS. The business's revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher's dividend payout ratio is currently 27.23%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. UBS Group reduced their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research note on Wednesday, July 23rd. Wells Fargo & Company reduced their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 23rd. Rothschild Redb downgraded Danaher from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 8th. Bank of America reduced their price objective on Danaher from $230.00 to $220.00 and set a "buy" rating for the company in a research note on Monday, September 22nd. Finally, Guggenheim reissued a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $245.00.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.